{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336867","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2026-08-06T12:17:10+00:00","discovered_at":"2026-08-06T12:20:00.284968+00:00","generated_at":"2026-08-06T12:20:04.426102+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Annexon reports all 10 GBS patients in FORWARD study improved within days on tanruprubart","bullets":["All 10 patients showed rapid, clinically meaningful muscle strength improvement within 4 days of single 30 mg/kg infusion.","Four bedbound patients walked with/without assistance between day 2 and day 8; one ventilated patient off ventilator within 4 days.","Results consistent with Phase 3 data where ~90% improved by day 8; tanruprubart generally well-tolerated.","BLA submission targeted for Q4 2026; MAA under EMA review; GBS has ~22,000 annual U.S./Europe cases and >$20B U.S. burden.","CEO cites decade-long commitment to C1q-targeted approach for neuroinflammatory diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336867","json":"https://secwatch.observer/filing/0001193125-26-336867.json","markdown":"https://secwatch.observer/filing/0001193125-26-336867.md","text":"https://secwatch.observer/filing/0001193125-26-336867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312526336867/0001193125-26-336867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312526336867/d159969d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:20:04.426102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}